Maggot Debridement: An Alternative Method for Debridement by Gottrup, Finn & Jørgensen, Bo
Maggot Debridement: An Alternative Method for
Debridement
Finn Gottrup, MD, DMSci, and Bo Jørgensen, MD
Copenhagen Wound Healing Center, Department of Dermatology, Bispebjerg University Hospital,
Copenhagen, Denmark
Correspondence: fgottrup@post4.tele.dk
Published July 12, 2011
Debridement is an essential component to promote healing in a problem wound. Several
techniques are available including maggot debridement therapy (MDT). Objective: To
describe the efﬁcacy of MDT for treating problem wound especially diabetic foot ulcers.
Methods:Thetopiciselucidatedfromdifferentpointsofview:themodeofaction,when
to use, use in a practice, clinical results, and discussing the problem of creating evidence
fortheclinicaleffect.Results:LiteratureandownresultsdemonstratethatMDTisasafe
method with few side effects. Maggot debridement therapy is as good as or better than
conventional often surgical debridement, is more selective than surgical debridement,
decreases time to healing and stay of patients in the ward, and may decrease the risk of
major amputations. However, the evidence of these effects of MDT on the highest level
is presently lacking. A detailed description of how to use MDT in practice is provided
including a visual demonstration in a video. Conclusion: In spite of lacking clinical
evidence, MDT clinical experience strongly suggests that this technique is effective and
safe. It can be used for most types of problem wounds, but our indication is primarily
diabetic foot ulcers, because of its selectivity for debriding necrotic dead tissue. It may
be a valuable alternative surgical/sharp debridement.
Previously, necrotic tissue like eschar or scab often like pus was looked upon as a
natural part of the healing process.1 More recently, however, it has been known that tissue
necrosis inﬂuences the healing process in a negative way resulting in a delayed or even
stoppedhealingprocess.Wounddebridementisforthesereasonsavitalpartofthetreatment
and healing of problem wounds.
Wound debridement is deﬁned as the removal of foreign material and dead contami-
nated tissue from (or adjacent to) a traumatic or infected lesion to expose healthy tissue. It
may also include removal of foreign material that has become embedded in the wound.2
The main reason for debriding a wound is to avoid substratum for bacterial growth,3,4
ongoing inﬂammation, and leukocyte inﬁltration with delayed progression to the prolifera-
tive and remodelling phases of wound healing,5,6 compromised restoration of the structure
and function of the skin,7 odor management issues, and other negative effects.
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Debridement is perhaps the most important part of the concept “Wound Bed Prepa-
ration” and wound management in general. Debridement must, however, not be seen in
isolation but should be regarded as one element to achieve healing.8
Several types of debridement are available.9,10 The most generally known is surgical
or sharp debridement, but nonsurgical methods have increasingly achieved attention dur-
ing the last years: enzymatic agents, chemical agents, autolytic debridement, biosurgical
debridement, wet-to-dry dressings, whirlpool and hydrotherapy, high-pressure irrigations,
and some other types of debridement. Debridement has been subdivided into selective and
nonselective methods depending on whether only nonviable tissue is removed. Selective
debridement methods can, for example, be mentioned as partial surgery, use of enzymes,
osmotic agents, autolysis, and maggot therapy.
The ﬁnal choice of debridement method is based on the wish of achieving the most
rapid,safe,andpainlesshealingofthewound.Toaccomplishthisgoal,thedebridementhas
to be sufﬁcient. This is attained when the wound bed consists entirely of healthy tissue.12
The beneﬁcial effects of maggots in the process of wound healing are known for
centuries. Since the last 15 years, maggot debridement therapy (MDT) is used in clinical
practices in Europe and the United States for the treatment of various types of severely
infected and necrotic wounds with successful healing results.13,14 Several historical doc-
uments prove that in ancient times, maggots, also known as “biosurgeons,” were already
applied for wound treatment.15 The Aboriginals in Australia and Maya tribes in Central
America used larvae frequently to clean wounds. William Baer (1872-1931), orthopedic
surgeon at the John Hopkins Hospital in Baltimore was the ﬁrst surgeon that employed lar-
vae of the Lucilia sericata type for the treatment of children with osteomyelitis in 1929.16
Baer described a fast debridement, the reduction of bacterial amounts, a decreased odor
andalkalinizationofthewoundsurface.Untilthe1940sAmericansurgeonsusedMDT,but
the discovery of Penicillin by Alexander Fleming in 1928 and the widespread production
and use of this ﬁrst antibiotic from 1944 leaded to the disappearance of maggots as a
treatment for infected wounds.17 However, only 4 years after the introduction of Penicillin,
morethan50%ofallStaphylococcusaureusspecimensproducedβ-lactamase,whichmade
them resistant to the mould.17 Bacterial resistance to Penicillin, and also to other types of
antibiotics, increased in the time afterwards, which resulted in the failed healing of infected
wounds, and because of this, maggots made their comeback in the late 1980s.18 In the
following years, MDT was reintroduced in United States and Europe using maggots of the
type Lucilia sericata.19-22
The aim of this clinical article is to describe the mode of action, when to use MDT, the
practical use of MDT in debridement, clinical results, and discuss the problem of creating
evidence for the clinical effect of MDT.
METHODS
Mode of action of MDT
Maggot’s debridement has been suggested to work by mechanical and biochemical
techniques.23,24 Mechanical debridement is caused by the speciﬁc mandibles or “mouth
hooks” of the maggots and their rough body which both scratch the necrotic tissue.
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Furthermore, maggots produce excretions and secretion (ES) that possess proteolytic
enzymes that can dissolve the dead and/or infected matrix on the wound bed.24
However, the long-standing hypothesis was that the mechanical debridement was one of
the responsible mechanisms for the effectiveness of MDT, but the current studies do not
support this objective and show more evidence for the biochemical mechanisms underlying
to its success.25
Maggots excretions and secretions contain allanto¨ ın, sulfhydryl radicals, calcium,
cysteine, glutathione, embryonic growth stimulating substance, growth stimulating factors
forﬁbroblasts,carboxypeptidasesAandB,leucineaminopeptidase,collagenase,andserine
proteases (trypsin-like and chymotrypsin-like enzymes, metalloproteinase and aspartyl
proteinase).26
A recent in vivo study possiblysupports the theory that the direct mechanicalaction of
free-range maggots is limited. In this research, larval therapy with free-range maggots and
maggotsinBiobagswascomparedwithhydrogelapplicationandshowedfasterdebridement
with the maggots.27 Although the maggots in Biobags needed 28 days to debride and free-
range maggots needed only 14 days, both therapies were very effective in debridement
compared to hydrogel, which cleaned the wounds in 72 days.
Maggot ES can prevent, inhibit, and break down bioﬁlms of various bacteria on com-
monly used prosthetic materials, and thus, it may in the future provide a new treatment
of bioﬁlm-associated infections of orthopedic biomaterials.28 On the contrary, the antimi-
crobial effect seems limited against pseudomonas bioﬁlm. An in vitro study has shown
reduced antimicrobial effect against Quorum sensing controlled pseudomonas aeruginosa
virulence factors.29
The type of maggot used in MDT is Lucilia sericata, whose actions are limited to the
necrotic wound and which spares the healthy tissue. Table 1 is summarizing the expected
mode of action for maggot debridement.30
Table 1. Maggot debridement: expected mode of action
Debridement Ingesting necrotic tissue. High proteolytic effect
liqueﬁes necrotic tissue.
Kill Bacteria Ingested bacteria are killed in the gut of the maggots
Environmental Production of ammonia increases pH and inhibits
growths of bacteria
Stimulate wound healing combined effect of mentioned
earlier effects. Direct stimulatory mechanical effect?
Inhibit Bioﬁlm Inhibit and break down bioﬁlms of various bacteria
Side effects: There are no severe side effects reported on MDT. Sometimes, a tickling
feelingofthecrawlingmaggotsisnoted;however,afterusingthecapturedmethod,thereare
fewer complaints about this sensation. Exceptional cases, for example, from patients with
leg ulcers, who are suffering from ischemic disease, report an increased pain by MDT,31
and in spite of neuropathy in diabetic foot ulcers (DFU), a type of pain can be experienced
in a few of these patients. The origin of reported pain during maggot application is not
known, because the wound-healing effect of maggots is not related to their direct crawling
action in the wound surface. No allergic reactions were ever noted.
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When to use MDT
Indications/contraindications: Maggot debridement therapy can be used for acute and
chronic wounds requiring debridement. In literature, the reported success rate varies from
80% to 90%.32 Clinical relevant indications are DFU, ischemic leg ulcers, osteomyelitis,
burn wounds, as postoperative treatment for a necrotizing fasciitis or for the prevention of
(further) amputations.19,32-34 In venous leg ulcers, however, maggot seems to have limited
effect.27
Maggot debridement therapy is contraindicated when there are open wounds into the
abdominalcavity,becauseoftheriskoforganlesions.Othercontraindicationsarepyoderma
gangrenosum in patients with immunosuppressive therapy and septic arthritis.31,35 Caution
is advised in treating wounds near to large arteria and veins. Wounds heavily contaminated
with pseudomonas aeruginosa may have limited effect of maggot debridement.29 Very dry
wound may be a relative contraindication because maggots require a moist environment.20
Practice clinical use of MDT
Currently there are 2 modes of application of MDT. First freely crawling maggots (Fig 1)
can be applied to the wound bed and covered by a nylon net. On the top of this is placed a
gauze bandage to keep the maggots captured in the wound and to let them breath freely. A
quantity of up to 10 maggots per square centimeter wound surface for 3 days consecutively
are used in our institution. After this period, the maggots should be removed by washing
out the wound by saline.
Figure 1. Freely crawling maggots.
In the second mode, maggots are captured and enclosed in special biobag containing
a polyvinyl alcohol spacer36 (Fig 2). The network of the biobag is permeable and permits
the migration of maggot ES to the wound. This bag facilitates the application of MDT and
also the inspection of the wound bed during the treatment at any time. The effectiveness
of the MDT captured in bags or in free-range application seems to be equal,36 but in case
of complicated undermined cavity wound-free maggots may be preferable. We advise to
use a quantity of 5 to 10 maggots per square centimeter wound surface for 3 to 4 days
consecutively after which the bags containing maggots should be replaced in combination
with a saline cleaning of the wound.37 Furthermore, it is necessary to use a physiological
salinesolutiondailytokeepthesurfacewet.Ithas,however,tobeborninmindthatexcessive
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ﬂushing could drown the maggots. In addition, it is advised to change the covering gauze
bandage daily to prevent odor and avoid the dressing to be ﬁlled with wound ﬂuid, which
could drown the maggots.
Figure 2. Maggots in a bag.
Sometimes, there are concerns about the resistance from patients to the utilization of
MDT, but many reports show in accordance with our observations that patient acceptability
is high.38 Information materials in form of handouts and posters is facilitating acceptance
in patients and relatives.
RESULTS
Literature
Maggot debridement has been used on different types of problem wounds like pressure
ulcers,39,40venouslegulcers,27,41DFU,42-45peripheralarterialdiseases,46andacutesurgical
wounds as treatment47 and as preparation for surgical wound closure.48
Maggot debridement therapy has been used for both out- and inpatients and reported
to have a success rate between 67% and 88%.31,39,44,49-51 Nevertheless, studies with direct
comparison between a maggot and control group has only been lesser performed. In a
study on pressure ulcers, MDT showed a success rate of 80% compared to 48% when using
conventional debridement.40
Diabetic foot ulcer patients are a major indication for MDT, and some comparative
studies have been published. In a study on DFU,44 conventional therapy after 5 weeks
showed that in this group more than 33% of the wound surface still was covered by necrotic
tissue, while all wounds in the MDT group after 4 weeks were completely debrided. Both
studies showed a shorter stay on the ward of the hospital, and one study has demonstrated
a lower need for amputations after MDT.51 In patients with neuroischemic diabetic foot
wounds and peripheral vascular disease, it has been demonstrated a shorter healing time
after MDT, a 3 times higher risk for undergoing amputation in the control group and
signiﬁcant more antibiotic-free days in the MDT group.46
SimilarresultswereshowninanothercomparativeDFUstudy.ItwasshownthatMDT
(using Lucilia cuprina maggots) is as effective as conventional surgical debridement, and
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there was an overall amputation rate of 20% in the MTD group compared with 38% in the
surgical debridement group.44 The outcome and decrease in amputation level, however, did
not reach statistical signiﬁcant, perhaps because of the low number of patients included in
the study.
In a recent randomized controlled trial (RCT) in venous leg ulcers,27 267 patients
were included. It was found that healing was not signiﬁcantly different between the loose
or bagged larvae group and the hydrogel group, but the larvae therapy reduced the time
to debridement. In this study, mean ulcer-related pain scores were higher for both types of
larvae treatment than for hydrogel treatment.
Afewstudieshavefocusedonthecost-effectivenessofMDT.Waymanetal52 prospec-
tively measured personal and material costs of treating venous leg ulcers with MDT or
hydrogel. The cost of treatment per patient in the MDT group was £79 compared to £136
for the hydrogel group (P < .05). The MDT group also required fewer visits to achieve
full debridement than controls. If nursing costs were included the total expenditure to full
debridement of one wound, the difference would have been 6 times lower in the MDT
group.53 For DFU, it has been calculated that the use of MDT may save almost £50 million
annually in the United Kingdom.54
Practice in Copenhagen Wound Healing Center (CWHC)
Practice in Copenhagen Wound Healing Center is a specialized wound healing institution
establishedasafull-integratedhospitalunitinthesocializedgovernmenthealthcaresystem
of Denmark.55-58 The Center consists of outpatient clinics and inpatient wards with 15 beds
only for patients with severe wounds of all etiologies. The multidisciplinary staffs consist
of doctors (surgeons, dermatologists), nurses (specialized), podiatrists, physiotherapists,
researchers, etc.
InDFUpatients,especiallydebridement,treatmentofinfection,woundphase–speciﬁc
conventional local wound treatment, ofﬂoading, and arterial revisualization have been
implemented. Implementation of this treatment has reduced the major amputation rate to
20% of what it was 15 years ago. All types of modern debridement systems are used
including MDT.
The CWHC introduced MDT in Denmark and presently more than 300 patients have
been treated and the method to treat has been locally published.59,60 The main indication
has been DFU. The reason for choosing this indication is that it is critical in this group of
patient to provide a type of debridement, which is as selective as possible to avoid tissue
damage as much as possible. In the DFU patient, exposed bone, especially at the heel area,
often results in a major amputation. The maggots are in this case much more selective than
the surgeon performing a sharp debridement. In CWHC, all DFU treatments have been
performed as an inpatient procedure.
The ﬁrst 16 DFU patientstreated by MDT in CWHC were presented in 2002 in Dublin
and Oxford. The wounds were of signiﬁcant size (mean = 31 × 47 mm), and all wounds
were necrotic. Although 44% of the patients had critical ischemia (toe pressure < 30 mm
Hg), a total of 88% had an improvement of granulation tissue development after MDT.
Total healing was achieved in 25% patients, whereas 19% of the patients, all with a toe
pressure of less than 30 mm Hg underwent major amputation.
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Since then, we have been using MDT routinely as a debridement method in case of
severe necrosis except for dry black necrosis, which need to be removed before the use of
maggots. This has resulted in the recommendations for the procedure of MDT shown in
Table 2.
Table 2. Recommendations for the procedure of maggot debridement therapy
Application of the maggots
Freely crawling maggots:
1. Primarily the wound boarder is drawn on a ﬁlm (Fig 3) and the template is used for the wound “opening” in a
hydrocolloid dressing. The skin wound surroundings are protected by a barrier ﬁlm (eg, Cavelon No Sting).
2. The opening in the hydrocolloid is placed exactly on the wound edges to protect the wound surroundings
(Fig 4). In case of very superﬁcial wounds, 2 layers of hydrocolloid can be put on to make the cavity large
enough for the maggots.
3. The maggots are removed from the container by using of few mL of saline (Fig 5). The maggots is placed
on the net which is included in the maggots shipment should use 10 maggots/cm2 surface area of the wound
(Fig 6).
4. The net is turned to place the maggots into the wound cavity (Fig 7). The net is ﬁxed with water safe wound
tape on the hydrocolloid surface. Be sure it is tight.
5. A nonwoven gauze slightly moisture by saline is then placed on the surface of the net (Fig 8) to give
humidity to the maggots, which is needed to survive in the initial phase. Later the maggots produce the
humidity by their own secretion.
6. Then, more (dry) nonwoven gauze is placed on the top of the moistured gauze and ﬁxed by gauze bandage
(Fig 9). The patient is then mobilized without pressure on the maggots. Compression bandages is not
allowed.
Maggots in a bag:
1. The bag is placed directly in the wound cavity.
2. Similar to the procedure point 5 and 6 for the freely crawling maggots.
Observation of the maggots:
At day 0, day 1 and 2.
The most superﬁcial dressing is lifted and removed if fully soaked (otherwise the maggots will drown). The
activity of the maggots is observed.
If very wet conditions in the wound dry nonwoven gauze is placed on the net, if dry in the wound use moisture
nonwoven gauze. If secretion is observed at the surface of the bandage, it should be changed at once.
Pain is normally not a problem, but in case of vasculitis wounds there can be intensive pain reactions (use
VAS-scale to observe).
In case or bleeding the treatment often has to be stopped.
Removal of the maggots:
The wound is ﬂushed by saline/water and the maggots are removed into a plastic bag. A forceps is used to
remove eventually maggots left. The maggots are destroyed together with other hospital garbage.
Bio bags is removed in Toto and destroyed together with other hospital garbage.
The wound is observed for an eventual new treatment by maggots.
An observation record of the maggot treatment should be ﬁlled out for each patient.
Video
The procedures described earlier are demonstrated on the attached video. [Click here]
DISCUSSION
This clinical article describes the mode of action, the time when to use MDT, the practical
use of MDT in debridement, clinical results, and practical recommendations. Maggot
debridement therapy has been shown as a safe and cost-effectivetreatment in contrastto the
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less selective surgical debridement and the use of expensive antibiotics. It has further been
shown that patients treated for MDT have a shorter stay at the hospital ward and patients
treated for DFU have a reduced need for amputation, and in these types of patients an
improved or at least a comparable effect to conventional debridement in terms of outcome
have been found.
Figure 3. Drawing the wound.
Figure 4. Film template cut out of hydrocol-
loid.
Figure 5. Maggots in container.
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Figure 6. Maggots on the net.
Figure 7. Net with maggots placed in the
wound.
Figure 8. Nonwoven gauze place on the net.
Why is MDT not yet a fully integrated debridement technique worldwide? This is
probably related to the sparse evidence on the highest level available for the effect of
MDT. Most of the studies on debridement61,62 and maggots are relatively small and present
insufﬁcient numbers to fulﬁll the Cochrane system demands, and the conclusion then is
that there is insufﬁcient evidence of the effects and more research is needed.
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Figure 9. Fixation by gauze bandage.
Similarproblemsarefoundforwoundmanagementingeneral,whereapaucityofhigh-
quality evidence is found, because studies often are based on inadequate sample size, short
follow-up, nonrandom allocation to treatment arms, nonblinded assessment of outcomes,
poor description of control, and concurrent intervention.63,64 The ongoing dilemma is to
address the requirements of a high-quality RCT, as demanded by regulatory authorities,
and to produce evidence relevant to clinicians working within the ﬁeld.65 Another major
issue relates to the choice of an appropriate population and endpoints to test the value of a
speciﬁc intervention in a speciﬁc condition.66 A successful and accepted outcome for high-
quality RCT, therefore, is linked to an adequate sample size (number of patients), sufﬁcient
follow-up time, random allocation, blinded assessment of outcomes, correct description of
control, and concurrent intervention. These issues will be very difﬁcult to fulﬁll in a RCT
where MDT is one of the investigated arms but should be taken into account every time a
study protocol is completed.
Besides the structure of the protocol and clinical effect of MDT, future studies should
try to further clarify the mechanism behind MDT. An important area to investigate is the
composition of maggot ES and determine the effective substances that are responsible for
the debridement, including the remodeling effect on the extracellular matrix components
and the reduction of bioﬁlm formation. In a recent defended PhD thesis, 38 different
proteases and new insect defensin (a type of antibiotic) were detected.67
CONCLUSIONS
The maggots of Lucilia sericata are especially indicated for wounds that need debridement.
At present, 2 modes of application are available—the free range and the captured method.
Bothmethodsareeffective,butinunderminedcavitywound-freemaggotsmaybepreferred.
Maggot debridement therapy also reduces bioﬁlm formation and has a positive effect on
extracellular matrix components.
Even though clinical evidence on the highest level of the effect of MDT is lacking, the
clinical experience strongly suggests that the technique is an effective and safe method of
debridement for some wound patients such as those with DFU.
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